| CASR — Calcium-Sensing Receptor | |
|---|---|
| Symbol | CASR |
| Full Name | Calcium-Sensing Receptor |
| Chromosome | 3q21.1 |
| NCBI Gene | 846 |
| Ensembl | ENSG00000036828 |
| OMIM | 601199 |
| UniProt | Q9UII2 |
| Protein Class | GPCR (Class C), Metabotrophic glutamate receptor family |
| Expression | Brain (cerebellum, [hippocampus](/brain-regions/hippocampus), cortex), Parathyroid, Kidney, Pancreas |
The Calcium-Sensing Receptor (CASR) is a class C G protein-coupled receptor that functions as the principal sensor of extracellular calcium concentrations in the body. Originally characterized for its critical role in calcium homeostasis in parathyroid and kidney, CASR is now recognized as having significant functions in the central nervous system (CNS), where it participates in synaptic plasticity, neuronal excitability, and cellular responses to pathological stimuli[1].
CASR belongs to the metabotropic glutamate receptor family, which includes eight members (mGluR1-8) and the GABA[B] receptors. These receptors share a common architecture with a large extracellular venus flytrap (VFT) domain, a cysteine-rich domain, and a seven transmembrane domain. Unlike the ionotropic glutamate receptors that function as ligand-gated ion channels, metabotropic receptors modulate synaptic transmission through G protein-mediated signaling cascades.
The human CASR gene spans approximately 73 kb on chromosome 3q21.1 and comprises 11 exons. The coding sequence is highly conserved across mammals, reflecting the critical nature of calcium sensing in vertebrate physiology. The promoter region contains multiple transcription factor binding sites, allowing for tissue-specific expression and regulation by various hormonal and developmental signals.
Alternative splicing generates multiple CASR variants with different tissue distributions and functional properties. The most common splice variants differ in their C-terminal tail length, which affects receptor desensitization and trafficking. In the brain, specific splice variants are enriched in different neuronal populations, suggesting specialized functions in distinct brain regions.
The extracellular Venus flytrap (VFT) domain of CASR contains the calcium binding sites. Each receptor monomer has multiple calcium binding pockets within the VFT, with calcium ions coordinating to negatively charged amino acid residues. The binding of calcium induces conformational changes that transmit across the receptor to the intracellular domains.
The VFT domain also contains binding sites for various allosteric modulators, including L-amino acids (particularly aromatic and aliphatic amino acids), which potentiate calcium-induced receptor activation. This amino acid sensing function may have relevance to neuronal metabolism and stress responses.
The seven transmembrane helices form the canonical GPCR transmembrane bundle. The transmembrane domains contain binding sites for positive and negative allosteric modulators, including calcimimetics (e.g., cinacalcet) used clinically for treating secondary hyperparathyroidism, and calcilytics that act as receptor antagonists.
The intracellular C-terminal tail contains multiple serine and threonine residues that can be phosphorylated, as well as motifs for interaction with scaffolding proteins and downstream signaling molecules. CASR signals primarily through:
Upon activation, CASR triggers multiple downstream signaling cascades:
CASR is expressed throughout the central nervous system with particularly high levels in:
At the cellular level, CASR localizes to:
This widespread subcellular distribution suggests multiple roles in neuronal physiology, from synaptic transmission to dendritic integration and development.
In neurons, CASR participates in local calcium sensing at synapses. The extracellular calcium concentration at synaptic clefts changes during neuronal activity, with lower calcium during high-frequency firing. CASR may function as a sensor linking synaptic activity to adaptive responses.
CASR activation modulates synaptic plasticity, the cellular basis for learning and memory. Studies have shown that:
The mechanism involves modulation of NMDA receptor function, changes in intracellular calcium dynamics, and activation of downstream signaling pathways including CaMKII and CREB[2].
By modulating voltage-gated calcium channels and potassium channels, CASR affects neuronal excitability. CASR activation generally reduces neuronal firing rate through activation of calcium-activated potassium channels. This may serve as a negative feedback mechanism preventing excessive neuronal activation.
Under various stress conditions, CASR activation can be neuroprotective:
CASR has complex interactions with amyloid precursor protein (APP) processing and amyloid-beta (Aβ) metabolism. Several mechanisms have been proposed:
Studies in AD brain tissue have shown altered CASR expression patterns, with decreased expression in certain brain regions and increased expression in others. This dysregulation may contribute to the amyloid pathology characteristic of AD[3].
CASR signaling affects tau phosphorylation through multiple kinase pathways:
In Alzheimer's disease, CASR contributes to synaptic dysfunction through:
CASR plays a significant role in neuroinflammation, a key feature of AD pathogenesis:
In the substantia nigra, CASR is expressed in dopaminergic neurons and affects their survival:
Altered CASR expression has been documented in PD brain tissue, particularly in the substantia nigra. This dysregulation may contribute to the selective vulnerability of dopaminergic neurons in PD[4].
CASR may influence alpha-synuclein (α-syn) aggregation through:
Similar to AD, neuroinflammation plays a key role in PD pathogenesis, and CASR participates in:
In ALS, CASR dysregulation has been observed in:
The role of CASR in ALS is an emerging area of research with potential therapeutic implications.
Calcimimetic compounds that allosterically activate CASR have been developed for clinical use in secondary hyperparathyroidism. These compounds may have neuroprotective effects by:
However, CNS-penetrant calcimimetics are needed for direct central nervous system effects.
Calcilytic compounds that antagonize CASR have been explored for:
The therapeutic potential of calcilytics in neurodegenerative diseases remains to be explored.
Based on current understanding, several therapeutic approaches targeting CASR could be developed:
CASR expression or function may serve as a biomarker for:
Several fundamental questions about CASR in neurodegeneration remain:
Advancing the field requires:
The Calcium-Sensing Receptor (CASR) is a G protein-coupled receptor with emerging importance in neurodegenerative diseases. Originally characterized for its role in systemic calcium homeostasis, CASR is now recognized as having significant functions in the brain, where it affects synaptic plasticity, neuronal excitability, and neuroprotection.
In Alzheimer's disease, CASR contributes to amyloid processing, tau pathology, synaptic dysfunction, and neuroinflammation. In Parkinson's disease, CASR affects dopaminergic neuron survival, alpha-synuclein aggregation, and neuroinflammation. These connections make CASR an interesting therapeutic target, though significant research is needed to develop brain-penetrant modulators and understand the precise mechanistic connections.
Calcium-sensing receptor in brain: Novel insights into function. Cell Calcium. 2012. ↩︎
Calcium-sensing receptor and synaptic plasticity in neurodegeneration. Progress in Neurobiology. 2021. ↩︎
Calcium-sensing receptor in Alzheimer's disease pathogenesis. Journal of Alzheimer's Disease. 2018. ↩︎
Calcium-sensing receptor dysfunction in Parkinson's disease. Neurobiology of Aging. 2019. ↩︎